Men and women show similar survival outcome in stage IV breast cancer |
| |
| Affiliation: | 1. Department of Radiation Oncology, Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University, Xiamen, 361003, China;2. Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, 510060, China;3. Eye Institute of Xiamen University, Fujian Provincial Key Laboratory of Ophthalmology and Visual Science, Medical College of Xiamen University, Xiamen, 361000, China;4. Department of Ultrasound, The First Affiliated Hospital of Xiamen University, Xiamen, 361003, China;1. Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, USA;2. Department of Hepatobiliary and Pancreatic Surgery, Shanghai East Hospital, Tongji University, Shanghai, China;3. Department of Surgical, Gastroenterological and Oncological Sciences, University of Padova, Italy;1. Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland;2. School of Medicine, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands;1. Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre +, Maastricht, The Netherlands;2. Department of Surgery, Atrium Medical Center, Heerlen, The Netherlands;1. Second Department of Surgery, Democritus University of Thrace Medical School, Alexandroupoli, Greece;2. University of Pittsburgh Medical Center, Department of Medicine, Pittsburgh, PA, USA |
| |
| Abstract: | PurposeTo evaluate the clinicopathological features, patterns of distant metastases, and survival outcome between stage IV male breast cancer (MBC) and female breast cancer (FBC).MethodsPatients diagnosed with stage IV MBC and FBC between 2010 and 2013 were included using the Surveillance, Epidemiology, and End Results program. Univariate and multivariate Cox regression analyses were used to analyze risk factors for overall survival (OS).ResultsA total of 4997 patients were identified, including 60 MBC and 4937 FBC. Compared with FBC, patients with MBC were associated with a significantly higher rate of estrogen receptor-positive, progesterone receptor-positive, unmarried, lung metastases, and a lower frequency of liver metastases. Univariate and multivariate analyses showed no significant difference in OS between MBC and FBC. In the propensity score-matched population, there was also no difference in survival between MBC and FBC. Multivariate analysis of MBC showed that OS was longer for patients aged 50–69 years and with estrogen receptor–positive disease.ConclusionsThere was no significant difference in survival outcome between stage IV MBC and FBC, but significant differences in clinicopathological features and patterns of metastases between the genders. |
| |
| Keywords: | Metastatic breast cancer Male Female Survival Metastatic patterns |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
